Immunis
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
18301 Von Karman Ave, Irvine, California...Website
www.immunisbiomedical.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Immunis
Immunis is a private biotechnology company focused on the development of treatments for age-related and disease-related immune deficits. Immunis has developed a novel method to grow human stem cells for clinical use, and direct them to become highly pure populations of defined cells that secrete factors which benefit immune system development, modulation, and health. With age, every person experiences a reduction of factors which benefit immune system development, modulation, and health; the company's technology allows replacement of those factors. The company's product is all natural, all human, and represents a perfectly balanced set of immune modulators in naturally occurring relevant physiological concentrations. Immunis' first clinical trial is a Phase 1/2a study of the effectiveness of STEM in treating muscle atrophy, which every person experiences with age.Explore more
Immunis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Immunis has new funding data
Check out if Immunis is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Immunis
Click to see if Immunis had a recent Job posting/layoffs
Product Launch: Get notified when Immunis launches new products
Website visits: Recent activity has been detected on your website
Immunis, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Immunis recently announced quarterly report
Check if Immunis has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Immunis as Masked Content
Find 2 more new buyers
Compare Similar Companies to Immunis
Compare insights from companies similar to Immunis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immunis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immunis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immunis.
Immunis financials insights
Gather financial insights about Immunis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$10M
2025
Series A
$25M
Immunis Tech Stack
A closer look at the technologies used by Immunis
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Funding
Funding
Event
Events
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immunis
Sign Up For FreeTo access detailed company insights
Immunis is a private biotechnology company focused on the development of treatments for age-related and disease-related immune deficits. Immunis has developed a novel method to grow human stem cells for clinical use, and direct them to become highly pure populations of defined cells that secrete factors which benefit immune system development, modu... Read More
